연구동향 분석

Fosfomycin Dosing Regimens based on Monte Carlo Simulation for Treated Carbapenem-Resistant Enterobacteriaceae Infection

Kanchanasurakit Sukrit Santimaleeworagun Wichai Charles E. McPherson, III Piriyachananusorn Napacha Boonsong Benjawan Katwilat Papanin Saokaew Surasak 2020년

논문상세정보
인용/피인용
' Fosfomycin Dosing Regimens based on Monte Carlo Simulation for Treated Carbapenem-Resistant Enterobacteriaceae Infection' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • Carbapenem-Resistant Enterobacteriaceae
  • Fosfomycin
  • Monte Carlo
  • microbialsensitivitytests
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
111 0

0.0%

' Fosfomycin Dosing Regimens based on Monte Carlo Simulation for Treated Carbapenem-Resistant Enterobacteriaceae Infection' 의 참고문헌

  • Treatment and clinical outcome of Colistin-resistant Klebsiella pneumoniae bacteremia patients
    Prawang A [2020]
  • The situation of antimicrobial resistance in health service areas from January to June 2019
  • The revival of fosfomycin
  • The renoprotective effect of concomitant fosfomycin in the treatment of pulmonary exacerbations in cystic fibrosis
    Al-aloul M [2019]
  • The prevalence of colistin-resistant Gram-negative bacteria isolated from hospitalized patients with bacteremia
  • The plasmid-mediated fosfomycin resistance determinants and synergy of fosfomycin and meropenem in carbapenem-resistant Klebsiella pneumoniae isolates in Taiwan
    Tseng SP [2017]
  • Target site penetration of fosfomycin in critically ill patients
    Joukhadar C [2003]
  • Synergistic activity of fosfomycin–meropenem and fosfomycin–colistin against carbapenem resistant Klebsiella pneumoniae: an in vitro evidence
  • Synergistic activity of colistin/fosfomycin combination against carbapenemase-producing Klebsiella pneumoniae in an in vitro pharmacokinetic/pharmacodynamic model
    Wang J [2018]
  • Surviving sepsis campaign:international guidelines for management of sepsis and septic shock:2016
    Rhodes A [2017]
  • Risk factors and outcomes for the acquisition of carbapenem-resistant Gramnegative bacillus bacteremia : A retrospective propensity-matched case control study
    Ting SW [2018]
  • Predicting efficacy of antiinfectives with pharmacodynamics and Monte Carlo simulation
    Bradley JS [2003]
  • Phenotypic detection of carbapenemase-producing organisms from clinical isolates
    Tamma PD [2018]
  • Pharmacokinetics/pharmacodynamics of antibacterials in the Intensive Care Unit : setting appropriate dosing regimens
    Scaglione F [2008]
  • Pharmacodynamics of fosfomycin against ESBL-and/or carbapenemase-producing Enterobacteriaceae
    Fransen F [2017]
  • Pharmacodynamics of fosfomycin : insights into clinical use for antimicrobial resistance
  • Pharmacodynamic evaluation of the potential clinical utility of fosfomycin and meropenem in combination therapy against KPC-2-producing Klebsiella pneumoniae
    Albiero J [2016]
  • Oral and intravenous fosfomycin in complicated urinary tract infections
  • Optimizing intravenous fosfomycin dosing in combination with carbapenems for treatment of Pseudomonas aeruginosa infections in critically ill patients based on pharmacokinetic/pharmacodynamic(PK/PD)simulation
    Asuphon O [2016]
  • Optimization of fosfomycin doses for treating Pseudomonas aeruginosa infection in critically ill patients by using Monte Carlo simulation
  • Monte Carlo simulations : maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients
    Roberts JA [2011]
  • KDIGO clinical practice guidelines for acute kidney injury
    Khwaja A [2012]
  • Intravenous fosfomycin for the treatment of hospitalized patients with serious infections
    Shorr AF [2017]
  • Infections caused by carbapenem-resistant Enterobacteriaceae : An update on therapeutic options
    Sheu CC [2019]
  • In vivo pharmacokinetics and pharmacodynamics of ZTI-01(Fosfomycin for injection)in the neutropenic murine thigh infection model against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa
    Lepak AJ [2017]
  • In vitro antibiotic synergy colistin-resistant Klebsiella pneumoniae
    Prawang A [2019]
  • Fosfomycin for injection(ZTI-01)versus piperacillin-tazobactam for the treatment of complicated urinary tract infection including acute pyelonephritis : ZEUS, a phase 2/3 randomized trial
    Kaye KS [2019]
  • Fosfomycin : Mechanism and resistance
    Silver LL [2017]
  • Fosfomycin
    Falagas ME [2016]
  • Extracellular concentrations of fosfomycin in lung tissue of septic patients
    Matzi V [2010]
  • Exploration of the pharmacokinetic-pharmacodynamic relationships for fosfomycin efficacy using an in Vitro infection model
    VanScoy BD [2015]
  • Deciphering pharmacokinetics and pharmacodynamics of fosfomycin
  • Critical issues for Klebsiella pneumoniae KPCcarbapenemase producing K. pneumoniae infections : a critical agenda
    De Rosa FG [2015]
  • Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections
    Roussos N [2009]
  • Clinical breakpoints -breakpoints and guidance
  • Carbapenem resistance: a review
    Codjoe FS [2017]
  • Biofilm-forming by carbapenem resistant enterobacteriaceae may contribute to the blood stream infection
    Yaita K [2019]
  • Augmented renal clearance in critically ill patients : a systematic review
  • Augmented renal clearance in critical illness : An important consideration in drug dosing
    Mahmoud SH [2017]
  • Adverse events associated with intravenous fosfomycin
    Florent A [2011]
  • A review on colistin nephrotoxicity